Bacteriophage therapy: back to the future | CMAC

Bacteriophage therapy: back to the future

Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1):55-64

​ Perepanova T.S., Kazachenko A.V., Khazan P.L., Malova Yu.A.
10.36488/cmac.2021.1.55-64
bacteriophages phages infections therapy
Section
Antimicrobials
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2021; 23(1):55-64

Abstract

In connection with growing problem of antimicrobial resistance, the search for alternative treatments for infection is popular topic nowadays. This article represents an overview of published data on the therapeutic use of bacteriophages, specifically in urinary tract infections. The history of phage therapy of infectious diseases from the beginning of the 20th century to the present days is presented. The paper also discuss the mechanism of bacteriophages activity, differences between lytic and lysogenic phages, mechanisms of bacterial tolerance to phages and ways of its overcoming are. Authors present their own data on 30 years of clinical use of “bacteriophage cocktails” in the treatment and prevention of urological infection.

Tamara S. Perepanova

Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia

Kazachenko A.V.

Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia

Khazan P.L.

Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia

Malova Yu.A.

Institute of Urology and Interventional Radiology named after N.A. Lopatkin, Moscow, Russia

  • 1. Centers for Disease Control. Antibiotic Resistance: The Global Threat. 2015; Accessed Mar 29, 2017. Available at: www.cdc.gov/drugresistance/pdf/antibiotic_resistant_fs.pdf.
  • 2. World Health Organization. Antibiotic resistance – a threat to global health security. 2013. Accessed Mar 29, 2017. Available at: www.who.int/drugresistance/activities/wha66_side_event/en/.
  • 3. Bourdin G., Navarro A., Sarker S.A., Pittet A.C., Qadri F., Sultana S., et al. Coverage of diarrhoea-associated Escherichia coli isolates from different origins with two types of phage cocktails. Microb Biotechnol. 2014;7:165176. DOI: 10.1111/1751-7915.12113
  • 4. Donlan R.M. Preventing biofilms of clinically relevant organisms using bacteriophage. Trends Microbiol. 2009;17:66-72. DOI: 10.1016/j.tim.2008.11.002
  • 5. Chanishvili N. Phage therapy – history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res. 2012;83:3-40. DOI: 10.1016/B978-012-394438-2.0000 1-3
  • 6. Lin D.M., Koskella B., Lin H.C. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162-173. DOI: 10.4292/wjgpt.v8.i3.162
  • 7. Crawford D.H. Viruses: A Very Short Introduction. Oxford University Press; 1st edition (September 1, 2011), 156 p.
  • 8. Delbrück M. The growth of bacteriophage and lysis of the host. J Gen Physiol. 1940;23(5):643-660. DOI: 10.1085/jgp.23.5.643
  • 9. Weinbauer M.G. Ecology of prokaryotic viruses. FEMS Microbiol Rev. 2004;28:127-181. DOI: 10.1016/j.femsre. 2003.08.001
  • 10. Steinier R., Edelberg E., Ingram D. The Microbial World. Vol. 1. Mir, M., 1979, 320 p. Russian.
  • 11. Cutter E., Sulakvelidze A. Bacteriophages. Biology and practical applications. Nauchnyj mir, 2012, 640 p. Russian.
  • 12. Penadés J.R., Chen J., Quiles-Puchalt N., Carpena N., Novick R.P. Bacteriophage-mediated spread of bacterial virulence genes. Curr Opin Microbiol. 2015;23:171-178. DOI: 10.1016/ j.mib.2014.11.019
  • 13. Modi S.R., Lee H.H., Spina C.S., Collins J.J. Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome. Nature. 2013;499:219222. DOI: 10.1038/nature12212
  • 14. Crawford D.H. Viruses: A Very Short Introduction. Oxford University Press; 1st edition (September 1, 2011), 150 p.
  • 15. Rakhuba D.V., Kolomiets E.I., Dey E.S., Novik G.I. Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol. 2010;59:145155. PMID: 21033576
  • 16. Perepanova T.S. Complex treatment and prevention of hospital urinary tract infection. Russian. PhD Thesis, Moscow, 1996, 54 p. Russian.
  • 17. Bogovazova G.G. Study of biological properties and therapeutic efficacy of Klebsiella bacteriophage preparations. PhD Thesis, Chelyabinsk, 1993, 27 p. Russian.
  • 18. Voroshilova N.N. Bacteriophage preparations and their effectiveness in the treatment of enteral and purulentseptic infectious diseases caused by opportunistic bacteria. Information materials. «NPO Immunopreparat», 1996, Ufa, 17 p. Russian.
  • 19. Sabouri Ghannad M., Mohammadi A. Bacteriophage: time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran J Basic Med Sci. 2012;15(2):693-701. PMID: 23494063
  • 20. Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8:317327. DOI: 10.1038/nrmicro2315
  • 21. Maciejewska B., Olszak T., Drulis-Kawa Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application? Appl Microbiol Biotechnol. 2018;102:25632581. DOI: 10.1007/s00253-018-8811-1
  • 22. Levin B.R., Bull J.J. Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol. 2004;2(2):166-173. DOI: 10.1038/nrmicro822
  • 23. Rohde C., Resch G., Pirnay J.P., Blasdel B.G., Debarbieux L., Gelman D., et al. Expert opinion on three phage therapy related topics: bacterial phage resistance, phage training and prophages in bacterial production strains. Viruses. 2018;10(4):178. DOI: 10.3390/v10040178
  • 24. Ofir G., Melamed S., Sberro H., Mukamel Z., Silverman S., Yaakov G., et al. DISARM is a widespread bacterial defence system with broad anti-phage activities. Nat Microbiol. 2018;3(1):90-98. DOI: 10.1038/s41564-017-0051-0
  • 25. Goldfarb T., Sberro H., Weinstock E., Cohen O., Doron S., Charpak-Amikam Y., et al. BREX is a novel phage resistance system widespread in microbial genomes. EMBO J. 2015;34(2):169-183. DOI: 10.15252/embj.201489455
  • 26. Swarts D.C., Jore M.M., Westra E.R., Zhu Y., Janssen J.H., Snijders A.P., et al. DNA-guided DNA interference by a prokaryotic Argonaute. Nature. 2014;507:258-261. DOI: 10.1038/nature12971
  • 27. Bondy-Denomy J., Pawluk A., Maxwell K.L., Davidson A.R. Bacteriophage genes that inactivate the CRISPR/Cas bacterial immune system. Nature. 2013;493:429-432. DOI: 10.1038/nature11723
  • 28. Torres-Barcelo C. Phage therapy faces evolutionary challenges. Viruses. 2018;10. pii: E323. DOI: 10.3390/v10060323
  • 29. Stanley S.Y., Borges A.L., Chen K.H., Swaney D.L., Krogan N.J., Bondy-Denomy J., Davidson A.R. AntiCRISPR-associated proteins are crucial repressors of antiCRISPR transcription. Cell. 2019;178:1452-1464.e1413. DOI: 10.1016/j.cell.2019.07.046
  • 30. d’Herelle F. Sur un microbein visible antagoniste des bacteries dysenteriques. C.R. Acad. Sci. 1917;165:373375. DOI: 10.4161/bact.1.1.14941
  • 31. Sulakvelidze A., Alavidze Z., Morris J.G.. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45:649659. DOI: 10.1128/AAC.45.3.649-659.2001
  • 32. Akimkin V.G., Efimenko N.A. The use of bacteriophages in the practice of treating various pathologies of a surgical and therapeutic profile. Methodical recommendations, M., 1998, 24 p. Russian.
  • 33. Hodyra-Stefaniak K., Miernikiewicz P., Drapała J., Drab M., Jończyk-Matysiak E., Lecion D., et al. Mammalian HostVersus-Phage immune response determines phage fate in vivo. Sci Rep. 2015;5:14802. DOI: 10.1038/srep14802
  • 34. Carlton R.M. Phage therapy: past history and future prospects. Arch Immunol Ther Exp (Warsz). 1999;47:267274. PMID: 10604231
  • 35. Hicks L.A., Bartoces M.G., Roberts R.M., Suda K.J., Hunkler R.J., Taylor T.H., Schrag S.J. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60:1308-1316. DOI: 10.1093/cid/civ076
  • 36. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013;13:1057-1098. DOI: 10.1016/S1473-3099(13)70318-9
  • 37. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1-12. DOI: 10.1086/595011
  • 38. Centers for Disease Control and Prevention. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013;62:165-170. PMID: 23466435
  • 39. Luepke K.H., Suda K.J., Boucher H., Russo R.L., Bonney M.W., Hunt T.D., Mohr J.F. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy. 2017;37:71-84. DOI: 10.1002/phar.1868
  • 40. Parfenyuk R.L. Microbiological bases of oral phage therapy of pyoinflammatory diseases. PhD Thesis, M., 2004, 24 p. Russian.
  • 41. Trushkov A.G. Problems of perinatology and reproductive health: Collection of scientific papers dedicated to the 25th anniversary of the Department of obstetrics and gynecology of Perm State Medical Academy. Perm, 2002, p. 213-215. Russian.
  • 42. Subbotin A.V., Funker E.V., Urman M.G., Horovits E.S., Maslov Yu.N., Odintsova O.V. Health and education: Proceedings of the international scientific and practical conference. Perm, 2006, p. 191-197. Russian.
  • 43. Tokarev M.V., Davidov M.I., Funkner E.V. Topical issues of clinical medicine: collection of scientific papers dedicated to the 130th anniversary of the Perm City Clinical Hospital №6. Perm, 2005, p. 45-47. Russian.
  • 44. Lazareva E.B. Bacteriophages for the treatment and prevention of infectious diseases. Antibiotiki i himioterapija. 2003;48(1):36-40. Russian.
  • 45. Gostishchev V.K., Stanoevich U.S., Aleshkin V.A., Afanasyev S.S. Tertiary peritonitis: the possibilities of its prevention. Hirurgija. 2007;9:15-18. Russian.
  • 46. Khairullin I.N., Pozdeev O.K., Shaimardanov R.Sh. The effectiveness of the use of specific bacteriophages in the treatment and prevention of surgical postoperative infections. Kazanskij medicinskij zhurnal. 2002;83(4):258261. Russian.
  • 47. Kutateladze M., Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect. 2008;38:426-430. DOI: 10.1016/j.medmal.2008.06.023
  • 48. Kutateladze M., Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2012;28:591-595. DOI: 10.1016/j.tibtech.2010.08.001.
  • 49. Slopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz). 1987;35:569-583. PMID: 3455647
  • 50. Lang G., Kehr P., Mathevon H., Clavert J.M., Sejourne P., Pointu J. [Bacteriophage therapy of septic complications of orthopaedic surgery (author’s transl]. Rev Chir Orthop Reparatrice Appar Mot. 1979;65:33-37. PMID: 156386
  • 51. Prokopenko E.I., Shherbakova E.O., Vatazin A.V., Budnikova N.E., et al. The use of a bacteriophage for the treatment of septic complications in patients with renal allografts. Urologiia. 2005;6:43-46. Russian.
  • 52. Perepanova T.S., Darbeeva O.S., Kotlyarova G.A., Kondratyeva E.M., Maiskaya L.M., Malysheva V.F., et al. The effectiveness of bacteriophage preparations in the treatment of inflammatory urological diseases. Urologija i nefrologija. 1995;5:14-17. Russian.
  • 53. Zorkin S.N., Shakhnovskiy D.S. Possibilities of bacteriophage therapy in the treatment of patients with complicated urinary tract infection. Pediatricheskaja farmakologija. 2013;10(4):132-138. Russian. DOI: 10.15690/pf.v10i4.767
  • 54. Anikina T.A., Ryazanova S.Kh., Sergeeva E.N. Freshly isolated strains of pathogens are the most important component in the production of adapted therapeutic and prophylactic bacteriophages. «ImBio». Nizhny Novgorod: Vaccinology, 2006; p. 3. Russian.
  • 55. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322. DOI: 10.1126/science.284.5418.1318
  • 56. Tolordava E.R. The role of bacterial biofilms in the etiopathogenesis of urolithiasis. PhD Thesis, M., 2014, 26 p. Russian.
  • 57. Ferry T., Leboucher G., Fevre C., Herry Y., Conrad A., Josse J., et al. Salvage debridement, antibiotics and implant retention (“DAIR”) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureus prosthetic-joint infection? 2018;5(11):ofy269. DOI: 10.1093/ofid/ofy269
  • 58. Nir-Paz R., Gelman D., Khouri A., Sisson B.M., Fackler J., Alkalay-Oren S., et al. Successful treatment of antibiotic resistant poly-microbial bone infection with bacteriophages and antibiotics combination. Clin Infect Dis. 2019;69:20152018. DOI: 10.1093/cid/ciz222
  • 59. Onsea J., Soentjens P., Djebara S., Merabishvili M., Depypere M., Spriet I., et al. Bacteriophage application for difficult-to-treat musculoskeletal infections: development of a standardized multidisciplinary treatment protocol. Viruses. 2019;11(10):891. DOI: 10.3390/v11100891
  • 60. Tkhilaishvili T., Winkler T., Muller M., Perka C., Trampuz A. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64(1):e00924-19. DOI: 10.1128/AAC.00924-19
  • 61. Wright A., Hawkins C.H., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34:349-357. DOI: 10.1111/j.17494486.2009.01973.x
  • 62. Fadlallah A., Chelala E., Legeais J.M. Corneal infection therapy with topical bacteriophage administration. Open Ophthalmol J. 2015;9:167-168. DOI: 10.2174/1874364101509010167
  • 63. Totté J.E.E., van Doorn M.B., Pasmans S.G.M.A. 2017. Successful treatment of chronic Staphylococcus aureusrelated dermatoses with the topical endolysin Staphefekt SA.100: a report of 3 cases. Case Rep Dermatol. 2017;9(2):19-25. DOI: 10.1159/000473872
  • 64. Jennes S., Merabishvili M., Soentjens P., Pang K.W., Rose T., Keersebilck E., et al. Use of bacteriophages in the treatment of colistin-only-sensitive Pseudomonas aeruginosa septicaemia in a patient with acute kidney injury – a case report. Crit. Care. 2017;21:129. DOI: 10.1186/s13054017-1709-y
  • 65. Jault P., Leclerc T., Jennes S., Pirnay J.P., Que Y.A., Resch G., et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 2019;19(1):35-45. DOI: 10.1016/S1473-3099(18)30482-1
  • 66. Rohde C., Wittmann J., Kutter E. Bacteriophages: a therapy concept against multi- drug-resistant bacteria. Surg Infect (Larchmt). 2018;19:737-744. DOI: 10.1089/sur.2018.184
  • 67. Perepanova T.S., Merinov D.S., Kazachenko A.V., Khazan P.L., Malova Yu.A. Prevention of infectious and inflammatory complications after percutaneous nephrolithotripsy. Urologija. 2020;3:26-34. Russian. DOI: 10.18565/urology.2020.3.26-33
  • 68. Malik D.J., Sokolov I.J., Vinner G.K., Mancuso F., Cinquerrui S., Vladisavljevic G.T., et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 2017;249:100-133. DOI: 10.1016/j.cis.2017.05.014
  • 69. Onsea J., Wagemans J., Pirnay J.P., Di Luca M., GonzalezMoreno M., Lavigne R., et al. Bacteriophage therapy as a treatment strategy for orthopaedic-device-related infections: where do we stand? Eur Cell Mater. 2020;39:193-210. DOI: 10.22203/eCM.v039a13
  • 70. Merabishvili M., Monserez R., van Belleghem J., Rose T., Jennes S., De Vos D., et al. Stability of bacteriophages in burn wound care products. PLoS One. 2017;12:e0182121. DOI: 10.1371/journal.pone.0182121
  • 71. Cisek A.A., Dabrowska I., Gregorczyk K.P., Wyzewski Z. Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages. Curr Microbiol. 2017;74:277-283. DOI: 10.1007/s00284-016-1166-x
  • 72. Roach D.R., Leung C.Y., Henry M., Morello E., Singh D., Di Santo J.P., et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22:38-47.e34. DOI: 10.1016/j.chom.2017.06.018
  • 73. Aleshkin A.V., Sel’kova E.P., Ershova O.N., Savin I.A., Shkoda A.S., Bochkareva S.S., et al. Concept of personalized phage therapy for intensive care unit patients with healthcare-associated infections. Fundamental'naja i klinicheskaja medicina. 2018;3(2):66-73. Russian. DOI: 10.23946/2500-0764-2018-32-66-74
  • 74. Abedon S.T., Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010;11:28-47. DOI: 10.2174/138920110790725410
  • 75. Dufour N., Delattre R., Ricard J.D., Debarbieux L. The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by betalactams. Clin Infect Dis. 2017;64:1582-1588. DOI: 10.1093/cid/cix184
  • 76. Van Belleghem J.D., Merabishvili M., Vergauwen B., Lavigne R., Vaneechoutte M. A comparative study of different strategies for removal of endotoxins from bacteriophage preparations. J Microbiol Methods. 2017;132:153-159. DOI: 10.1016/j.mimet.2016.11.020
  • 77. Kutter E., De Vos D., Gvasalia G., Alavidze Z., Gogokhia L., Kuhl S., Abedon S.T. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol. 2010;11:69-86. DOI: 10.2174/138920110790725401
  • 78. Pires D.P., Oliveira H., Melo L.D., Sillankorva S., Azeredo J. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol. 2016;100:2141-2151. DOI: 10.1007/s00253-0157247-0
  • 79. Payne R.J., Jansen V.A. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42:315325. DOI: 10.2165/00003088-200342040-00002
  • 80. Chan B.K., Abedon S.T., Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 2013;8(6):769-783. DOI: 10.2217/fmb.13.47
  • 81. Loc-Carrillo C., Abedon S.T. Pros and cons of phage therapy. Bacteriophage. 2011;1:111-114. DOI: 10.4161/bact.1.2.14590
Views
0 Abstract
0 PDF
0 Crossref citations
Shared